Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Gianluca Pirozzi

Dupilumab in Moderate-To-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus Aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2020English

Related publications

Laboratory Safety of Dupilumab in Moderate‐to‐severe Atopic Dermatitis: Results From Three Phase III Trials ( LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS )

British Journal of Dermatology
DermatologyMedicine
2019English

Pss43 - Dupilumab Improves Absenteeism in Moderate-To-Severe Atopic Dermatitis Patients Compared With Placebo in Phase 3 Liberty Ad Solo Studies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-To-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

IgE Testing Can Predict Food Allergy Status in Patients With Moderate-Severe Atopic Dermatitis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Group 2 Innate Lymphoid Cells in Patients With Severe Atopic Dermatitis on Dupilumab

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Efficacy and Safety of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults

Oncotarget
Oncology
2017English

615 Dupilumab Elicits Rapid and Sustained Improvements in Itch in Adults With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy